Get the Stockscreener App
9.44
3.17%
0.29
After Hours:
9.44
Xilio Therapeutics Inc stock is traded at $9.44, with a volume of 10,092.
It is up +3.17% in the last 24 hours and up +22.60% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
See More
Previous Close:
$9.15
Open:
$9.14
24h Volume:
10,092
Relative Volume:
0.23
Market Cap:
$62.07M
Revenue:
$43.77M
Net Income/Loss:
$-35.04M
P/E Ratio:
-2.9027
EPS:
-3.2521
Net Cash Flow:
$-5.51M
1W Performance:
+1.83%
1M Performance:
+22.60%
6M Performance:
-2.99%
1Y Performance:
-3.40%
1-Day Range:
$8.91
$9.53
1-Week Range:
$8.91
$9.89
52-Week Range:
$6.4652
$12.74
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
9.44 | 62.99M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
XLO Stock Price, Quote & Chart - ChartMill
Price to sales forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer By Investing.com - Investing.com Nigeria
Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer - marketscreener.com
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - citybiz
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer - Investing.com
Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief - Stock Titan
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Optimism Amid Pipeline ProgressEPS Estimate Trend - dars.gov.et
Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell Microcap Index - marketscreener.com
Enterprise value to revenue forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell 3000E Value Benchmark - marketscreener.com
XLO Forecast — Price Target — Prediction for 2027 - TradingView
Xilio Therapeutics Inc Actuals & Estimates (NASDAQ:XLO) - TradingView
Xilio Therapeutics Inc (XLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XLO Price Today: Xilio Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Xilio Therapeutics Inc (XLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xilio Therapeutics Inc (XLO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xilio Therapeutics Inc (XLO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xilio Therapeutics Inc (XLO) Institutional Confidence - TradingKey
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes - The Globe and Mail
Daniel Curran reappointed to Class III director at Xilio - TradingView
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options - Stock Titan
Xilio (XLO) director receives grant of 5,000 stock options at $7.99 - Stock Titan
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options at $7.99 - Stock Titan
Xilio Therapeutics (XLO) director Xu Yuan receives grant of 5,000 stock options - Stock Titan
Xilio Therapeutics (XLO) director receives 5,000 stock options at $7.99 strike - Stock Titan
Xilio Therapeutics (XLO) director granted options for 5,000 shares at $7.99 - Stock Titan
Board changes and stock plan vote at Xilio Therapeutics (NASDAQ: XLO) - Stock Titan
Top Lunai Bioworks (LNAI) Competitors 2026 - MarketBeat
Xilio Therapeutics (XLO) Edges Higher, Testing Resistance After Modest GainsGolden Cross - newsline.com
XLO Q1 2026 Earnings: Narrower Loss Surprises, Clinical Progress ContinuesReturn On Capital - newsline.com
XLO News | XILIO THERAPEUTICS INC (NASDAQ:XLO) - ChartMill
Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update - Bez Kabli
[EFFECT] Xilio Therapeutics, Inc. SEC Filing - Stock Titan
Xilio Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesPreliminary Results - newsline.com
Xilio Therapeutics (XLO) Holds Near Resistance as Price Action Remains Range-BoundTrend Continuation Trade - dars.gov.et
Xilio Therapeutics (XLO) Shows Resilience with 1.91% Gain, Testing Key ResistanceVWAP Breakout - The Legal Advocate
Xilio Therapeutics (NASDAQ: XLO) amends shelf to include $14.5M ATM and updated exhibits - Stock Titan
XLOXilio Therapeutics Inc Stock Price and Quote - Finviz
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Yield Analysis - The Legal Advocate
Is Xilio Therapeutics (XLO) Still a Buy After +2.89% Rally? 2026-05-21Wyckoff Upthrust - Newser
Xilio Therapeutics (XLO) Crushes Q1 2026 Estimates — EPS $-0.58 Tops ViewsHigh Interest Stocks - Newser
Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView
Xilio Therapeutics, Inc. (XLO) reports Q1 loss, beats revenue estimates - MSN
Xilio Therapeutics (XLO) Stock Analysis: Falls -5.11%, Watching $7.94 2026-05-17Technical Analysis - Newser
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):